News
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: q.beyond accelerates AI transformation and adjusts outlook for 2026 financial year
q.beyond accelerates AI transformation and adjusts outlook for 2026 financial year. Management decides to align with new technological and macroeconomic conditions, impacting full-year outlook -
-
COMMUNIQUÉ DE PRESSE
Infracore SA announces partial exercise of the over-allotment option
Infracore SA announces partial exercise of the over-allotment option. Joint Global Coordinators acquire additional shares in the IPO at CHF 54.00 per share. Sale of 4,413,139 registered shares generates CHF 238.3 million -
-
-
-
-
COMMUNIQUÉ RÉGLEMENTÉ
BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Biophytis secures approval from ANVISA for OBA clinical trial in Brazil, advancing BIO101 drug candidate for obesity treatment. Key milestone in multinational clinical development
